Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saved in:
| Title: | Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. |
|---|---|
| Authors: | Saif MW; Tufts Cancer Center - Medical Center, Tufts University School of Medicine, 800 Washington St., Ste. 7099, 7-South, Boston, MA, 02111, USA. wsaif@tuftsmedicalcenter.org., Knost JA; Illinois CancerCare, Peoria, IL, USA., Chiorean EG; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kambhampati SR; Eli Lilly and Company, Bridgewater, NJ, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Pytowski B; Eli Lilly and Company, New York, NY, USA., Qin A; Eli Lilly and Company, Bridgewater, NJ, USA., Kauh JS; Eli Lilly and Company, Bridgewater, NJ, USA., O'Neil BH; Indiana University, Indianapolis, IN, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Oct; Vol. 78 (4), pp. 815-24. Date of Electronic Publication: 2016 Aug 26. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 27566701 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Saif+MW%22">Saif MW</searchLink>; Tufts Cancer Center - Medical Center, Tufts University School of Medicine, 800 Washington St., Ste. 7099, 7-South, Boston, MA, 02111, USA. wsaif@tuftsmedicalcenter.org.<br /><searchLink fieldCode="AU" term="%22Knost+JA%22">Knost JA</searchLink>; Illinois CancerCare, Peoria, IL, USA.<br /><searchLink fieldCode="AU" term="%22Chiorean+EG%22">Chiorean EG</searchLink>; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Kambhampati+SR%22">Kambhampati SR</searchLink>; Eli Lilly and Company, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Yu+D%22">Yu D</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Pytowski+B%22">Pytowski B</searchLink>; Eli Lilly and Company, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Qin+A%22">Qin A</searchLink>; Eli Lilly and Company, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kauh+JS%22">Kauh JS</searchLink>; Eli Lilly and Company, Bridgewater, NJ, USA.<br /><searchLink fieldCode="AU" term="%22O'Neil+BH%22">O'Neil BH</searchLink>; Indiana University, Indianapolis, IN, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2016 Oct; Vol. 78 (4), pp. 815-24. <i>Date of Electronic Publication: </i>2016 Aug 26. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=27566701 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00280-016-3134-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 815 Titles: – TitleFull: Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Saif MW – PersonEntity: Name: NameFull: Knost JA – PersonEntity: Name: NameFull: Chiorean EG – PersonEntity: Name: NameFull: Kambhampati SR – PersonEntity: Name: NameFull: Yu D – PersonEntity: Name: NameFull: Pytowski B – PersonEntity: Name: NameFull: Qin A – PersonEntity: Name: NameFull: Kauh JS – PersonEntity: Name: NameFull: O'Neil BH IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2016 Oct Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1432-0843 Numbering: – Type: volume Value: 78 – Type: issue Value: 4 Titles: – TitleFull: Cancer chemotherapy and pharmacology Type: main |
| ResultId | 1 |
